Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. 15 Μαΐ 2024 · Total direct estimated costs of diagnosed diabetes increased from $227 billion in 2012 to $307 billion in 2022 (2022 dollars). Total indirect costs increased from $89 billion to $106 billion in the same period (2022 dollars). From 2012 to 2022, excess medical costs per person associated with diabetes increased from $10,179 to $12,022 (2022 ...

  2. 1 Μαΐ 2014 · A report by Diabetes UK bringing together evidence on the health economics of diabetes and the leading interventions to help people with diabetes and reduce costs to the NHS.

  3. 1 Νοε 2023 · The total estimated cost of diagnosed diabetes in the U.S. in 2022 is $412.9 billion, including $306.6 billion in direct medical costs and $106.3 billion in indirect costs attributable to diabetes.

  4. 11 Ιουν 2020 · We classified the interventions based on their strength of evidence (strong, supportive, or uncertain) and levels of CE: cost-saving (more health benefit at a lower cost), very cost-effective (≤$25,000 per life year gained [LYG] or quality-adjusted life year [QALY]), cost-effective ($25,001–$50,000 per LYG or QALY), marginally cost ...

  5. 12 Απρ 2018 · The cost of care for people with diabetes now accounts for ∼1 in 4 health care dollars spent in the U.S. Care for a person with diabetes now costs an average of $16,752 per year. As in prior reports, the 2017 analysis also documents substantial indirect costs related to lost productivity due to diabetes and its complications.

  6. Objectives We explore the cost of care of type 2 diabetes mellitus (T2DM) using time-driven activity-based costing (TDABC) and connect that cost to resulting patient health outcomes. Design We construct six care pathways varying from low-risk to high-risk patients over a 12-month cycle of care.

  7. 1 Μαΐ 2020 · This paper aims to more exactly quantify the net impact of diabetes on different aspects of healthcare provision in hospitals in England, building on previous work that looked at the determinants of outcome in type 1 diabetes (T1DM) and type 2 diabetes (T2DM).